Create Account

One Health helps you track and understand your health simply.

Create Account

One Health helps you track and understand your health simply.

Factor XII Activity (1:40)

Coagulation

Factor XII activityFXIIHageman factor activity

Review status

Currently under review

Pending specialist review and validation.

What it shows

This test measures the activity of coagulation Factor XII, a protein that helps start the intrinsic pathway of blood clotting. The assay uses a defined dilution to standardize how the sample triggers a clotting reaction in the laboratory, and reports how well Factor XII is functioning relative to normal plasma.

Factor XII is produced in the liver and is part of the contact activation system, which also links to inflammation and the kallikrein-kinin pathway. Unlike many other clotting factor deficiencies, low Factor XII activity typically prolongs screening clotting tests but does not usually cause abnormal bleeding.

Why it matters

Your clinician may order this test when a screening clotting test such as the aPTT is unexpectedly prolonged, especially if you do not have a history of easy bleeding. Measuring Factor XII activity helps distinguish a true factor deficiency from other causes of a prolonged aPTT, such as an inhibitor or an anticoagulant medication. It can also clarify results before procedures, evaluate potential inherited deficiency, or investigate certain pregnancy or thrombotic histories when appropriate.

Understanding Factor XII is important because very low activity often does not predict bleeding during surgery or injury, yet it can affect how other coagulation tests look. Some studies have explored links between Factor XII levels and thrombosis or pregnancy complications, but these associations are not consistent, and results should be interpreted in the context of your overall health.

Understanding your results

If your result is lower than expected, your provider will consider whether this reflects an inherited deficiency, an acquired change such as liver disease or significant illness, or an effect from medications that interfere with clot-based assays. A low result by itself usually does not mean you are at higher risk of bleeding, but it can explain a prolonged aPTT in someone who does not bleed more than usual. Your clinician may review other factor assays, mixing studies, or tests for inhibitors to provide a complete picture.

If your result is within the expected range, Factor XII deficiency is unlikely to be the reason for an abnormal screening test. If it is higher than expected, this is rarely clinically significant on its own but can be seen with certain physiological or inflammatory states. Always discuss results with your clinician, who may suggest repeating testing when you are not taking anticoagulants, checking additional coagulation studies, or considering genetic testing if there is a strong suspicion of an inherited condition.

Reference ranges

0.41.5 U/mL
All sexes
0 days – 150 years

Reference intervals vary by laboratory, analyzer, methodology, population, and units. The ranges shown here are for education only. Always interpret your results against the reference interval printed on your own lab report.

Factors that could impact Factor XII Activity (1:40)

  • Anticoagulant medications

    Heparin, direct oral anticoagulants, and some parenteral agents can interfere with clot-based factor activity assays, making Factor XII activity appear lower than it truly is. Tell your clinician about all blood thinners so timing or alternative methods can be considered.

  • Specimen collection and handling

    Improper tube filling, delayed processing, or contamination from a line that contains heparin can lead to misleading results. Using the correct citrate tube, ensuring a proper fill, and prompt centrifugation and freezing when required help maintain accuracy.

  • Lupus anticoagulant and inhibitors

    Phospholipid-dependent inhibitors such as lupus anticoagulant can prolong clot-based reactions and falsely lower factor activity estimates. Your laboratory may use additional tests or different assay formats to reduce this effect and clarify results.

  • Liver function and severe illness

    Factor XII is synthesized in the liver. Advanced liver disease, disseminated intravascular coagulation, or significant systemic inflammation can reduce activity and complicate interpretation, so results are considered alongside clinical findings.

  • Hormones, pregnancy, and inflammation

    Physiologic changes with pregnancy, estrogen therapy, or inflammatory states can shift contact system proteins and slightly alter measured activity. Your provider will interpret results in the context of these conditions.

  • Age and neonatal samples

    Newborns and young infants can have different levels of contact factors compared with adults, which may influence activity results. Pediatric interpretation often relies on age-appropriate context and, if needed, repeat testing.

2026

References

  1. McGill University Health Centre. (2015, March 01). Factor XII 1:40 (Task CD 702124). Laboratory reference ranges.
  2. Clinical and Laboratory Standards Institute. (2008). Collection, transport, and processing of blood specimens for testing plasma-based coagulation assays and molecular hemostasis assays, approved guideline (H21-A5). Wayne, PA: CLSI.
  3. Pengo, V., Tripodi, A., Reber, G., Rand, J. H., Ortel, T. L., Galli, M., & De Groot, P. G. (2009). Update of the guidelines for lupus anticoagulant detection. Journal of Thrombosis and Haemostasis, 7(10), 1737–1740.
  4. Adcock, D. M., Gimenez, M. M., Kressin, D. C., Marlar, R. A., Olson, J. D., & Favaloro, E. J. (2013). Collection, transport, and processing of blood specimens for testing plasma-based coagulation assays and molecular hemostasis assays: approved guideline update. Seminars in Thrombosis and Hemostasis, 39(3), 283–294.